PRESS RELEASE published on 01/09/2025 at 09:00, 1 year 2 months ago Important milestone for Biotest: Biologics License Application for Fibrinogen submitted to the US Food and Drug Administration (FDA) Biotest AG reaches a significant milestone by submitting a Biologics License Application for Fibrinogen to the US FDA, aiming to address fibrinogen deficiency FDA Biotest AG Fibrinogen Biologics License Application Medical Treatment
BRIEF published on 11/15/2024 at 09:05, 1 year 4 months ago Minister and Mayor Advocate for Plasma Donations at Biotest's Center Biotest AG Public Awareness Plasma Donations Darmstadt Healthcare Employment
BRIEF published on 11/15/2024 at 09:05, 1 year 4 months ago Le ministre et le maire plaident en faveur des dons de plasma au centre Biotest Biotest AG Sensibilisation Du Public Darmstadt Dons De Plasma Emploi Dans Le Secteur De La Santé
PRESS RELEASE published on 11/15/2024 at 09:00, 1 year 4 months ago Minister of Economic Affairs Mansoori and Lord Mayor Benz visit Biotest's plasma center in Darmstadt and call for plasma donations Minister of Economic Affairs Mansoori and Lord Mayor Benz visit Biotest's plasma center in Darmstadt to promote plasma donations and secure the long-term supply of plasma. Biotest AG emphasizes the importance of plasma donation in treating various illnesses Community Support Healthcare Biotest AG Plasma Donations Plasma Center
BRIEF published on 11/14/2024 at 10:19, 1 year 4 months ago Biotest Reports 4.5% Revenue Increase in First Nine Months of 2024 Financial Outlook Biotest Revenue Yimmugo® Growth Fibrinogen BT524 Grifols Agreement
BRIEF published on 11/14/2024 at 10:19, 1 year 4 months ago Biotest annonce une augmentation de son chiffre d'affaires de 4,5 % au cours des neuf premiers mois de 2024 Perspectives Financières Chiffre D'affaires De Biotest Croissance De Yimmugo® Fibrinogène BT524 Accord Grifols
PRESS RELEASE published on 11/14/2024 at 10:14, 1 year 4 months ago Biotest increases revenues in the first 9 months by 4.5% to Euro 523 million Biotest AG reports 4.5% revenue growth in first 9 months, reaching Euro 523 million. Product sales rise by 13.7%. Adjusted EBIT remains stable. Marketing authorization application submitted for Fibrinogen Concentrate (BT524). Outlook adjusted Revenue Growth EBIT Biotest AG Product Sales Marketing Authorization
BRIEF published on 11/14/2024 at 09:01, 1 year 4 months ago Biotest AG Revises Revenue, Cash Flow, and ROCE Forecasts for 2024 Revenue Growth Financial Forecast Biotest AG ROCE EBIT Guidance
BRIEF published on 11/14/2024 at 09:01, 1 year 4 months ago Biotest AG révise ses prévisions de revenus, de flux de trésorerie et de ROCE pour 2024 Biotest AG ROCE Prévisions Financières Croissance Des Revenus Prévisions EBIT
PRESS RELEASE published on 11/14/2024 at 08:56, 1 year 4 months ago EQS-Adhoc: Biotest AG: Biotest corrects forecast for revenue, cash flow and ROCE – EBIT guidance unchanged Biotest AG corrects forecast for revenue, cash flow, and ROCE while maintaining EBIT guidance. Details on the adjustments made for the 2024 financial year disclosed Revenue Cash Flow Biotest AG ROCE Forecast Correction
Published on 03/23/2026 at 14:05, 47 minutes ago Wellgistics Health Inc. Signs $105,000,000 Letter of Intent to Evaluate Potential Acquisition of Neuritek Therapeutics, Inc. which is Pioneering Innovative Therapies for Neurological and Psychiatric Disorders
Published on 03/23/2026 at 14:00, 52 minutes ago BlackBerry AtHoc Advances Command Center for Faster Response and Tighter Control During Critical Operations
Published on 03/23/2026 at 13:05, 1 hour 47 minutes ago SouthGobi Announces Disclosable and Connected Transaction Deferral of Payment Obligations Under Convertible Debenture and Amended and Restated Cooperation Agreement
Published on 03/23/2026 at 12:32, 2 hours 20 minutes ago Sinopec Announced 2025 Annual Results Annual Payout Ratio Reached 81%
Published on 03/23/2026 at 12:30, 2 hours 22 minutes ago Digi Power X to Announce 2025 Year End Financial Results on March 31st
Published on 03/23/2026 at 14:30, 22 minutes ago Solvias Earns EcoVadis Bronze Medal, Ranking in Top 35% of Companies for Sustainability Performance
Published on 03/23/2026 at 14:30, 22 minutes ago Belvilla Expands in Germany with Hambachtal Holiday Park in Oberhambach
Published on 03/23/2026 at 14:24, 28 minutes ago Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Published on 03/23/2026 at 08:10, 6 hours 42 minutes ago Entrée en négociations exclusives de cession de la participation dans Winncare
Published on 03/20/2026 at 19:00, 2 days 19 hours ago AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days 19 hours ago AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 20 hours ago Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 20 hours ago Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA